The UK Health Security Agency (UKHSA) has secured a shipment of the antiviral drug favipiravir (Avigan) from Japan’s national stockpile. The move follows a hantavirus outbreak aboard the MV Hondius, a cruise ship that recently crossed the Atlantic Ocean.
Thank you for reading this post, don't forget to subscribe!Because the UK has admitted passengers from the ship—including a Japanese national—for health monitoring and self-isolation, the British government requested the medication as a proactive safety measure.
Key Details of the Deployment
- The Treatment: Favipiravir is an antiviral developed in Japan. While there is no universally licensed cure for hantavirus, animal studies indicate that the drug may improve survival rates if administered early in the infection.
- International Cooperation: The shipment was authorized by Japan’s Ministry of Health, Labour and Welfare under an existing public health Memorandum of Cooperation. Japanese Health Minister Kenichiro Ueno confirmed that the dispatch would not compromise Japan’s own domestic reserves.
- Regulatory Adjustments: Because favipiravir is not currently licensed for standard medical use in the UK, British officials fast-tracked a liability indemnity agreement for the manufacturer and the Japanese government. The UK government deemed this step necessary to ensure immediate access to a viable medical countermeasure.
The UKHSA is actively monitoring asymptomatic contacts currently in isolation. The imported antiviral will be held in reserve and deployed immediately if any individuals test positive or develop severe symptoms.
